sdhd-1 Antibody

What is SDHD protein and why is it important in research?

SDHD (Succinate Dehydrogenase Complex, Subunit D, Integral Membrane Protein) is one of four proteins that constitute the tricarboxylic cycle enzyme succinate dehydrogenase complex. This protein has significant importance in metabolic signaling pathways and energy transfer processes in the mitochondria. Research has shown that mutations in SDHD often lead to hereditary paragangliomas, suggesting its crucial role as a tumor-suppressor gene . This makes SDHD antibodies valuable tools for investigating mitochondrial function, cellular metabolism, and oncological research.

What applications are SDHD-1 antibodies validated for?

SDHD antibodies have been validated for multiple research applications across various experimental systems:

Researchers should conduct preliminary titration experiments to determine optimal conditions for their specific experimental systems .

How do I select the right SDHD antibody for cross-species studies?

When selecting SDHD antibodies for cross-species applications, consider the following criteria:

• Verify species reactivity in manufacturer datasheets. Available SDHD antibodies show different reactivity patterns:

  • Human-only reactive antibodies

  • Human and rat cross-reactive antibodies

  • Human, mouse, and rat cross-reactive antibodies

• Confirm the immunogen sequence alignment with your target species. For example, one antibody was raised against a synthetic peptide within human SDHD aa 100 to the C-terminus , while another used a sequence near the N-terminal region (aa 20-50) .

• Review validation data specifically in your species of interest, as cross-reactivity can vary significantly between applications (e.g., an antibody may work for WB but not IHC in a particular species) .

What controls should be included when using SDHD-1 antibodies?

Proper experimental controls are essential for generating reliable data with SDHD antibodies:

• Positive tissue controls:

  • Human colon carcinoma and rat brain tissue

  • Human heart tissue

  • Human stomach cancer tissue

  • HepG2, HeLa, or Jurkat cell lysates for WB applications

• Negative controls:

  • Primary antibody omission control

  • Isotype control (rabbit IgG)

  • Blocking peptide competition (pre-incubation of antibody with immunizing peptide)

• Technical validation controls:

  • For WB: Molecular weight markers to confirm band size (expected ~17 kDa calculated, though observed molecular weights may vary)

  • For IHC/IF: Titration series to optimize signal-to-noise ratio

How should I optimize antigen retrieval for SDHD immunohistochemistry?

Successful immunohistochemical detection of SDHD requires careful optimization of antigen retrieval:

• Buffer selection:

  • Primary recommendation: TE buffer pH 9.0

  • Alternative option: Citrate buffer pH 6.0

• Retrieval method comparison:

  • Test both heat-induced epitope retrieval (HIER) and enzymatic retrieval methods

  • For HIER, optimize temperature, duration, and pressure parameters

  • Document tissue morphology preservation alongside antigen retrieval efficiency

• Tissue-specific considerations:

  • Fixation duration impacts retrieval requirements (longer fixation typically requires more aggressive retrieval)

  • Tissue type affects optimal retrieval parameters (e.g., different protocols for brain versus liver)

  • Fresh frozen tissues may require different or minimal retrieval procedures

What are the optimal sample preparation conditions for detecting SDHD in Western blots?

For optimal Western blot detection of SDHD:

• Sample extraction:

  • Use buffers containing 0.02% sodium azide and 50% glycerol at pH 7.3 to maintain protein stability

  • Include protease inhibitors to prevent degradation

  • For membrane proteins like SDHD, consider detergent-based extraction methods

• Protein loading and separation:

  • Load 15 μg/μl of RIPA protein lysate for reliable detection

  • Use 4-12% Bis-Tris gradient gels for optimal separation

  • Consider using 15% gels for better resolution of lower molecular weight proteins

• Transfer considerations:

  • Overnight transfer to Immobilon-FL membranes at low voltage improves transfer efficiency for membrane proteins

  • Wet transfer systems typically perform better than semi-dry for membrane proteins

How can SDHD antibodies be used to investigate mitochondrial dysfunction in disease models?

SDHD antibodies provide valuable tools for studying mitochondrial dysfunction:

• Co-localization studies:

  • Combine SDHD immunostaining with other mitochondrial markers to assess complex assembly

  • Investigate spatial reorganization of respiratory complexes in disease states

• Expression quantification:

  • Compare SDHD levels between normal and pathological samples

  • Correlate SDHD expression with clinical parameters in patient samples

• Functional correlation:

  • Link SDHD protein levels with succinate dehydrogenase enzymatic activity

  • Investigate metabolic consequences of SDHD mutations or expression changes

• Therapeutic monitoring:

  • Track SDHD expression changes in response to experimental treatments

  • Evaluate mitochondrial recovery in intervention studies

What approaches can resolve contradictory SDHD expression data between different detection methods?

When faced with discrepancies in SDHD expression data:

• Methodological evaluation:

  • Compare antibody epitopes - some antibodies detect only specific isoforms (e.g., some antibodies detect only the two longest isoforms of SDHD)

  • Assess protein extraction efficiency for different sample types

  • Evaluate fixation and processing effects on antigen detection

• Data integration strategies:

  • Correlate protein detection with mRNA expression

  • Use multiple antibodies targeting different epitopes

  • Implement orthogonal detection technologies (mass spectrometry)

• Biological validation:

  • Genetic manipulation (knockdown/knockout) to confirm specificity

  • Rescue experiments to verify antibody specificity

  • Cross-species comparison of expression patterns

How can I design experiments to investigate SDHD mutations and their impact on protein function?

For comprehensive analysis of SDHD mutations:

• Expression system development:

  • Generate cell lines expressing wild-type vs. mutant SDHD

  • Create isogenic lines with CRISPR-Cas9 gene editing

  • Develop inducible expression systems for temporal studies

• Functional assessment strategies:

  • Compare subcellular localization using immunofluorescence

  • Examine protein stability and turnover rates

  • Assess complex assembly using co-immunoprecipitation

• Structural-functional correlation:

  • Map mutation locations relative to antibody epitopes

  • Correlate protein expression patterns with enzymatic activity

  • Investigate post-translational modifications affected by mutations

How can I resolve multiple band detection issues in SDHD Western blots?

When encountering multiple bands in SDHD Western blots:

• Isoform identification:

  • At least four isoforms of SDHD are known to exist, and some antibodies detect only specific isoforms

  • Compare observed molecular weights with predicted isoform sizes

  • Use isoform-specific antibodies when available

• Non-specific binding evaluation:

  • Test increasing antibody dilutions (1:5000 to 1:50000 range recommended)

  • Implement more stringent washing conditions

  • Consider alternative blocking reagents

• Sample preparation refinement:

  • Ensure complete denaturation of protein complexes

  • Add reducing agents to disrupt potential disulfide bonds

  • Optimize sample heating time and temperature

What factors affect SDHD detection sensitivity in different experimental systems?

Several factors can impact SDHD detection sensitivity:

• Antibody-related factors:

  • Clonality (polyclonal vs. monoclonal) affects recognition breadth

  • Antibody affinity influences detection threshold

  • Storage conditions affect long-term performance (store at -20°C; avoid freeze/thaw cycles)

• Sample-related considerations:

  • Fixation methods significantly impact epitope accessibility

  • Expression levels vary between tissues and cell types

  • Post-translational modifications may mask epitopes

• Technical parameters:

  • Detection system sensitivity (chemiluminescence vs. fluorescence)

  • Signal amplification methods

  • Image acquisition and analysis approaches

How can I adapt protocols for detecting SDHD in challenging sample types or special experimental conditions?

For challenging experimental conditions:

• Formalin-fixed paraffin-embedded (FFPE) tissues:

  • Extended antigen retrieval with TE buffer pH 9.0

  • Sequential retrieval (heat followed by enzymatic digestion)

  • Signal amplification systems for low-abundance detection

• Flow cytometry applications:

  • Optimize permeabilization conditions for intracellular staining

  • Use approximately 0.4 μg antibody per 10^6 cells

  • Implement compensation controls for multi-parameter analysis

• Co-staining with other markers:

  • Carefully select compatible secondary antibodies

  • Consider sequential rather than simultaneous staining

  • Test for antibody cross-reactivity before experimental use

How should researchers interpret differences between calculated and observed molecular weights for SDHD?

The calculated molecular weight of SDHD is approximately 17 kDa , but observed molecular weights often differ:

What quantification methods provide the most reliable SDHD expression data?

For accurate SDHD quantification:

• Western blot analysis:

  • Use digital image acquisition with linear dynamic range

  • Implement appropriate normalization (total protein staining preferred for mitochondrial proteins)

  • Perform technical and biological replicates (minimum n=3)

• Immunohistochemistry quantification:

  • Apply digital image analysis with standardized parameters

  • Consider both staining intensity and distribution patterns

  • Use automated scoring systems to reduce subjective assessment

• Flow cytometry:

  • Report median fluorescence intensity rather than mean values

  • Use appropriate negative controls for gating

  • Apply standardized protocols across comparative samples

How can SDHD expression data be integrated with other molecular and functional datasets?

For comprehensive data integration:

• Multi-omics correlation approaches:

  • Link protein expression with transcriptomic data

  • Correlate with metabolomic profiles, particularly TCA cycle metabolites

  • Integrate with genomic data on SDHD mutations or variants

• Functional correlation strategies:

  • Associate SDHD levels with enzymatic activity measurements

  • Relate expression patterns to mitochondrial membrane potential

  • Connect protein data with cellular phenotypes (growth, metabolism)

• Clinical and biological context integration:

  • Correlate SDHD expression with patient data in disease studies

  • Evaluate expression changes in response to environmental factors

  • Consider temporal dynamics in developmental or intervention studies